April 2009
M	T	W	T	F	S	S
« Mar		May »
	1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30

Pharmacy Links

ARTHRITIS BEATEN TODAY: CMO (CERASOMAL-CIS-Q-CETYLMYRISTOLEATE)

28th April 2009

A STUDY ON DOSE EFFECTIVENESS AND PATIENT RESPONSE-SUMMARY

The results of this study lead to several conclusions regarding its five principal objectives:

1.) Optimum dosage levels appear to be equal for all three types of arthritis investigated: osteoarthritis, rheumatoid arthritis, and reactive psoriatic arthritis. This is evidenced by the gradual return of minor arthritis symptoms in several of those treated with only 16 or 24 capsules, and no regression in those treated with 50 capsules in two series separated by one week without treatment.

2.) Dosage level requirements appear to be equal irrespective of the severity of the subject’s condition.

3.) Initial response time for minor improvement appears to vary from two to seven days irrespective of the severity of the subject’s condition.

4.) The time for maximum attainable response appears to vary from seven to twenty-one days, resulting in 70% to 100% overall improvement. (Apart from this study, three of the most severely afflicted subjects were treated again after a five week interval, resulting in an additional 10% to 20% overall improvement.)

5.) The two non-responding subjects both proved to have suffered previous damage to the liver from steroid or alcohol abuse, indicating that impaired liver function may preclude success with this protocol.

In addition, it was evident that for many subjects the relief of inflammation resulted in marked improvement in joint deformation.

It is important to note that the substance utilized for oral administration in this study, CMO, was not an unmodified cetylmyristoleate, but the unique form of cetylmyristoleate

(cerasomal-cis-9-cetylmyristoleate) – produced using cerasomal techniques to give it a high level of bioavailability when taken orally. Free cetylmyristoleate liquid has very low levels of bioavailabilty orally, and is best utilized only as an injectable.

This study was conducted at the San Diego Clinic, Chula Vista, California, and several additional sites following a model prepared by the San Diego Clinic.

Note: This is the first ever human clinica study conducted, and it was done using only authentic CMO. We have seen promotional literature for other products referring to our study as if it applied to their products. It does not. Any such claim is fraudulent and we do not hesitate to take legal action against such criminal trickery.